Momelotinib
Momelotinib, a Janus Kinase 1 (JAK1) and 2 (JAK2) inhibitor, functions as a competitive inhibitor of JAK ATP binding. FDA-approved since September 15, 2023, this drug is specifically used in the treatment of myelofibrosis.
Myelofibrosis (MF) is a category of myeloproliferative neoplasms characterized by the abnormal proliferation of hematopoietic stem cells, leading to the secretion of cytokines and growth factors. Within the scope of MF are primary MF (PMF), post-polycythemia vera (PV) MF, and post-essential thrombocythemia (ET) MF.
Clinical symptoms of MF encompass anemia and thrombocytosis. Momelotinib’s mechanism of action involves blocking the JAK-signal transducer and activator of transcription (STAT) signaling pathway, which is dysregulated in myelofibrosis (MF).
Showing the single result
Last updated on 24-05-2025 15:07:03
Overview
Momelotinib, a Janus Kinase 1 (JAK1) and 2 (JAK2) inhibitor, functions as a competitive inhibitor of JAK ATP binding. FDA-approved since September 15, 2023, this drug is specifically used in the treatment of myelofibrosis.
Myelofibrosis (MF) is a category of myeloproliferative neoplasms characterized by the abnormal proliferation of hematopoietic stem cells, leading to the secretion of cytokines and growth factors. Within the scope of MF are primary MF (PMF), post-polycythemia vera (PV) MF, and post-essential thrombocythemia (ET) MF.
Clinical symptoms of MF encompass anemia and thrombocytosis. Momelotinib’s mechanism of action involves blocking the JAK-signal transducer and activator of transcription (STAT) signaling pathway, which is dysregulated in myelofibrosis (MF).
Related Posts:
No matching posts found.